A Brief Mobile-Augmented Suicide Prevention Intervention for People With Psychotic Disorders in Transition From Acute to Ongoing Care: Protocol for a Pilot Trial.
mental health services
prevention
psychosis
technology
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
08 Feb 2021
08 Feb 2021
Historique:
received:
12
04
2019
accepted:
26
11
2019
revised:
25
10
2019
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
People with serious mental illnesses (SMIs) are at exceptionally high risk for lifetime suicidal ideation and behavior compared with the general population. The transition period between urgent evaluation and ongoing care could provide an important setting for brief suicide-specific interventions for SMIs. To address this concern, this trial, SafeTy and Recovery Therapy (START), involves a brief suicide-specific cognitive behavioral intervention for SMIs that is augmented with mobile phone interactions. The primary aim of this pilot trial is to evaluate the feasibility, acceptability, and preliminary effectiveness of the intervention. A 6-month pilot trial with 70 participants with a diagnosis of bipolar disorder, schizophrenia or schizoaffective disorder, and current active suicidal ideation were randomized to START or START with mobile augmentation. START consists of 4 weekly sessions addressing early warning signs and triggers, symptoms influencing suicidal thinking, and social relationships. Recovery planning is followed by biweekly telephone coaching. START with mobile augmentation includes personalized automated cognitive behavioral therapy scripts that build from in-person content. Participants were evaluated at baseline, 4 weeks (end of in-person sessions), 12 weeks (end of telephone coaching), and 24 weeks. In addition to providing point estimates of feasibility and acceptability, the primary outcome of the trial was the change in severity of suicidal ideation as measured with the Scale for Suicide Ideation (SSI) and secondary outcome included the rate of outpatient engagement. The trial is ongoing. Feasibility and acceptability across conditions will be assessed using t tests or Mann-Whitney tests or chi-square tests. The reduction of SSI over time will be assessed using hierarchical linear models. The design considerations and results of this trial may be informative for adapted suicide prevention in psychotic disorders in applied community settings. ClinicalTrials.gov NCT03198364; http://clinicaltrials.gov/ct2/show/NCT03198364. DERR1-10.2196/14378.
Sections du résumé
BACKGROUND
BACKGROUND
People with serious mental illnesses (SMIs) are at exceptionally high risk for lifetime suicidal ideation and behavior compared with the general population. The transition period between urgent evaluation and ongoing care could provide an important setting for brief suicide-specific interventions for SMIs. To address this concern, this trial, SafeTy and Recovery Therapy (START), involves a brief suicide-specific cognitive behavioral intervention for SMIs that is augmented with mobile phone interactions.
OBJECTIVE
OBJECTIVE
The primary aim of this pilot trial is to evaluate the feasibility, acceptability, and preliminary effectiveness of the intervention.
METHODS
METHODS
A 6-month pilot trial with 70 participants with a diagnosis of bipolar disorder, schizophrenia or schizoaffective disorder, and current active suicidal ideation were randomized to START or START with mobile augmentation. START consists of 4 weekly sessions addressing early warning signs and triggers, symptoms influencing suicidal thinking, and social relationships. Recovery planning is followed by biweekly telephone coaching. START with mobile augmentation includes personalized automated cognitive behavioral therapy scripts that build from in-person content. Participants were evaluated at baseline, 4 weeks (end of in-person sessions), 12 weeks (end of telephone coaching), and 24 weeks. In addition to providing point estimates of feasibility and acceptability, the primary outcome of the trial was the change in severity of suicidal ideation as measured with the Scale for Suicide Ideation (SSI) and secondary outcome included the rate of outpatient engagement.
RESULTS
RESULTS
The trial is ongoing. Feasibility and acceptability across conditions will be assessed using t tests or Mann-Whitney tests or chi-square tests. The reduction of SSI over time will be assessed using hierarchical linear models.
CONCLUSIONS
CONCLUSIONS
The design considerations and results of this trial may be informative for adapted suicide prevention in psychotic disorders in applied community settings.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03198364; http://clinicaltrials.gov/ct2/show/NCT03198364.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/14378.
Identifiants
pubmed: 33555265
pii: v10i2e14378
doi: 10.2196/14378
pmc: PMC7899804
doi:
Banques de données
ClinicalTrials.gov
['NCT03198364']
Types de publication
Journal Article
Langues
eng
Pagination
e14378Subventions
Organisme : NIMH NIH HHS
ID : R34 MH113613
Pays : United States
Informations de copyright
©Colin Depp, Blaire Ehret, Jennifer Villa, Dimitri Perivoliotis, Eric Granholm. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 08.02.2021.
Références
J Consult Clin Psychol. 1974 Dec;42(6):861-5
pubmed: 4436473
J Clin Epidemiol. 2015 Nov;68(11):1375-9
pubmed: 26146089
Bipolar Disord. 2007 Sep;9(6):636-45
pubmed: 17845279
J Nerv Ment Dis. 2010 Oct;198(10):715-21
pubmed: 20921861
Am J Prev Med. 2014 Sep;47(3 Suppl 2):S186-94
pubmed: 25145738
J Affect Disord. 2015 Mar 15;174:23-30
pubmed: 25479050
J Consult Clin Psychol. 2015 Feb;83(1):92-102
pubmed: 25222800
Lancet Psychiatry. 2016 Jun;3(6):544-54
pubmed: 27017086
Schizophr Bull. 2009 Jul;35(4):696-703
pubmed: 19491314
Schizophr Res. 2014 Jul;156(2-3):204-10
pubmed: 24853059
Arch Gen Psychiatry. 2007 Aug;64(8):966-74
pubmed: 17679641
Am J Psychiatry. 2011 Dec;168(12):1266-77
pubmed: 22193671
Psychiatr Serv. 2005 Dec;56(12):1564-9
pubmed: 16339619
PLoS One. 2016 Apr 13;11(4):e0152285
pubmed: 27073900
Clin Transl Sci. 2011 Oct;4(5):332-7
pubmed: 22029804
JAMA Psychiatry. 2015 Mar;72(3):219-25
pubmed: 25715312
Arch Suicide Res. 2017 Jan 2;21(1):1-11
pubmed: 26821811
J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86
pubmed: 11132119
Am J Psychiatry. 2005 Mar;162(3):520-9
pubmed: 15741469
Arch Gen Psychiatry. 2010 Dec;67(12):1230-7
pubmed: 21135323
Suicide Life Threat Behav. 2015 Oct;45(5):600-611
pubmed: 25688921
Telemed J E Health. 2013 Dec;19(12):938-41
pubmed: 24050609
Focus (Am Psychiatr Publ). 2016 Apr;14(2):222-224
pubmed: 31975808
Ann Emerg Med. 2016 Dec;68(6):758-765
pubmed: 27451339
PLoS One. 2010 Oct 13;5(10):e13196
pubmed: 20967242
Schizophr Bull. 2012 May;38(3):414-25
pubmed: 22080492
J Consult Clin Psychol. 2016 Jun;84(6):544-57
pubmed: 27018530
J Psychiatr Res. 2006 Apr;40(3):221-30
pubmed: 16300791
Psychiatry Res. 2014 Dec 15;220(1-2):564-70
pubmed: 25155939
Psychiatr Serv. 2013 May 1;64(5):404-6
pubmed: 23632573
J Psychopharmacol. 2010 Nov;24(4 Suppl):81-90
pubmed: 20923923
Health Psychol. 2008 Mar;27(2S):S101-8
pubmed: 18377151
Aust N Z J Psychiatry. 2015 Sep;49(9):785-802
pubmed: 26185269
J Stat Softw. 2013 Sep;54(10):
pubmed: 24403868
Schizophr Bull. 2019 Jun 18;45(4):752-762
pubmed: 30281086
J Affect Disord. 2009 Feb;113(1-2):21-9
pubmed: 18676024
Arch Suicide Res. 2016 Jul 2;20(3):314-22
pubmed: 26649615
Psychol Assess. 2015 Jun;27(2):501-512
pubmed: 25496086
Schizophr Res. 2016 Apr;172(1-3):195-200
pubmed: 26948502
BMC Psychol. 2013 Apr 30;1(1):6
pubmed: 25566358
Lancet Psychiatry. 2016 May;3(5):443-50
pubmed: 26948484
Curr Opin Psychiatry. 2014 May;27(3):197-202
pubmed: 24613983
Clin Psychol Rev. 2011 Feb;31(1):89-103
pubmed: 21130939
Psychiatry Res. 2000 Dec 27;97(2-3):129-35
pubmed: 11166085
J Affect Disord. 2011 Mar;129(1-3):117-25
pubmed: 20889214
Br J Health Psychol. 2006 Sep;11(Pt 3):421-37
pubmed: 16870053
Curr Opin Psychol. 2018 Aug;22:33-37
pubmed: 30122275
Psychiatr Serv. 2005 Mar;56(3):344-6
pubmed: 15746510
J Clin Epidemiol. 2013 Feb;66(2):197-201
pubmed: 23195919
Schizophr Bull. 2008 May;34(3):507-14
pubmed: 17932087
Am J Psychiatry. 1999 Oct;156(10):1590-5
pubmed: 10518171
J Psychiatr Res. 2016 Aug;79:8-20
pubmed: 27128172
Crisis. 2020 May;41(3):233-236
pubmed: 31657642